1 Ocak 2022 Dergi makalesi Açık Erişim

Aksoy, Secil Ak; Tunca, Berrin; Ercelik, Melis; Tezcan, Gulcin; Ozturk, Ersin; Cecener, Gulsah; Ugras, Nesrin; Yilmazlar, Tuncay; Yerci, Omer

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Aksoy, Secil Ak</dc:creator>
  <dc:creator>Tunca, Berrin</dc:creator>
  <dc:creator>Ercelik, Melis</dc:creator>
  <dc:creator>Tezcan, Gulcin</dc:creator>
  <dc:creator>Ozturk, Ersin</dc:creator>
  <dc:creator>Cecener, Gulsah</dc:creator>
  <dc:creator>Ugras, Nesrin</dc:creator>
  <dc:creator>Yilmazlar, Tuncay</dc:creator>
  <dc:creator>Yerci, Omer</dc:creator>
  <dc:date>2022-01-01</dc:date>
  <dc:description>Background This study aimed to investigate the role of long noncoding RNA (LncRNA) expression profiles to predict relapse and 5-FU response in patients with stage I/II colon cancer (CC). Methods and Results The expression level of 15 LncRNA was analyzed in stage I/II colon tumors of 126 CC patients. To confirm the findings in-vitro, 5FU-resistant HT29 cells were generated by subjecting HT-29 cells to the increasing concentrations of 5FU for 6 months. The 5FU resistance was observed in WST-1 and Annexin V analyses. The colony formation and wound healing assays were assessed to determine the metastatic properties of the cells. Expression levels of LncRNAs and mRNA of EMT-related genes were determined by RT-PCR. The role of LncRNA on metastasis and 5FU sensitivity were confirmed in pcDNA3.0-PTENP1 and si-MALAT1 expressed 5FU-resistant HT29 cell lineages. Results High MALAT1 (p = 0.0002) and low PTENP1 (p = 0.0044) expressions were significantly associated with 5-FU resistance and tumor relapse in stage I/II CC. The invasiveness and colony-forming characteristics of 5-FU-resistant cell lineages were higher as compared to the parent HT-29. Moreover, the expression of MALAT1 (p = 0.0009) was increased while the expression of PTENP1 (p = 0.0158) decreased in 5FU-resistant-HT-29 cells. Si-MALAT1 treatment increased cell sensitivity to 5FU, whereas it decreased invasive behaviors of 5 FU-resistant-HT-29 cells. Conclusion MALAT1 may be a biomarker in predicting recurrence in early-stage CC. Our findings suggest that a cell-based therapy to target MALAT1 could be established for these patients to prevent metastasis and 5-FU resistance.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/258999</dc:identifier>
  <dc:identifier>oai:aperta.ulakbim.gov.tr:258999</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>MOLECULAR BIOLOGY REPORTS 49(12) 11243-11253</dc:source>
  <dc:title>Early-stage colon cancer with high MALAT1 expression is associated with the 5-Fluorouracil resistance and future metastasis</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>